Literature DB >> 15108803

Reversibility of oncogene-induced cancer.

Dean W Felsher1.   

Abstract

Cancer can largely be conceived as a consequence of genomic catastrophes resulting in genetic events that usurp physiologic function of a normal cell. These genetic events mediate their pathologic effects by either activating oncogenes or inactivating tumor-suppressor genes. The targeted repair or inactivation of these damaged gene products may counteract the effects of these genetic events, reversing tumorigenesis and thereby serve as an effective therapy for cancer. However, because they are the result of many genetic events, the inactivation of no single mutant gene product may be sufficient to reverse cancer. Despite this caveat, compelling recent evidence suggests that there are circumstances when even the brief interruption of activation of a single oncogene can be sufficient to reverse tumorigenesis. Understanding how and when oncogene inactivation reverses cancer will be important in both defining the molecular pathogenesis of cancer as well as developing new molecularly based treatments.

Entities:  

Mesh:

Year:  2004        PMID: 15108803     DOI: 10.1016/j.gde.2003.12.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  32 in total

Review 1.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 2.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

3.  Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling.

Authors:  Christian Berens; Stephanie Bisle; Leonie Klingenbeck; Anja Lührmann
Journal:  J Vis Exp       Date:  2015-06-25       Impact factor: 1.355

4.  The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth.

Authors:  Arvin M Gouw; Katherine Margulis; Natalie S Liu; Sudha J Raman; Anthony Mancuso; Georgia G Toal; Ling Tong; Adriane Mosley; Annie L Hsieh; Delaney K Sullivan; Zachary E Stine; Brian J Altman; Almut Schulze; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

5.  Genetic analysis of myc and telomerase interactions in vivo.

Authors:  Ignacio Flores; Gerard Evan; María A Blasco
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

6.  Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

Authors:  David I Bellovin; Bikul Das; Dean W Felsher
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Therapeutic Targeting of Myc.

Authors:  Edward V Prochownik; Peter K Vogt
Journal:  Genes Cancer       Date:  2010-06

8.  Tissue-specific and reversible RNA interference in transgenic mice.

Authors:  Ross A Dickins; Katherine McJunkin; Eva Hernando; Prem K Premsrirut; Valery Krizhanovsky; Darren J Burgess; Sang Yong Kim; Carlos Cordon-Cardo; Lars Zender; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2007-06-17       Impact factor: 38.330

9.  Diet-induced hepatocellular carcinoma in genetically predisposed mice.

Authors:  Annie E Hill-Baskin; Maciej M Markiewski; David A Buchner; Haifeng Shao; David DeSantis; Gene Hsiao; Shankar Subramaniam; Nathan A Berger; Colleen Croniger; John D Lambris; Joseph H Nadeau
Journal:  Hum Mol Genet       Date:  2009-05-19       Impact factor: 6.150

Review 10.  Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.

Authors:  Brooke B Ancrile; Kevin M O'Hayer; Christopher M Counter
Journal:  Mol Interv       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.